Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies
James A. Heslop(Liverpool City Council), B. Kevin Park(Liverpool City Council), Isabel Hopp(University of Liverpool), Enrique I. Graziano(Almirall (Spain)), David C. Hay(MRC Centre for Regenerative Medicine), Christopher E. Goldring(University of Liverpool), Alexis Caron, Uri Ben‐David(Tel Aviv University), Erik H.J. Danen(Leiden University), Ilaria Santeramo(University of Liverpool), Glyn Stacey, Petter Björquist, Thomas Hammond(University of Basel), John Mills(AstraZeneca (United Kingdom)), Giovanni Pellegrini(University of Zurich), Junnat Hamdam(Heinrich Heine University Düsseldorf), Dominic P. Williams(AstraZeneca (United Kingdom)), Daniel J. Antoine(Liverpool City Council), Michael Cross(University of Liverpool), Peter W. Andrews(University of Sheffield), Swaminathan Sethu(Vellore Institute of Technology University), Michaela Sharpe(Pfizer (United Kingdom)), Roua S. Baty(University of Liverpool), Patricia Murray(University of Liverpool), Jacqueline Piner(Centre for Research and Development), David Jones(German Cancer Research Center), Sara Patel(ReNeuron (United Kingdom)), Patrik Sköld(Uppsala University), Jens Reinhardt(Paul Ehrlich Institut), Cliff Rowe(CN Bio Innovations (United Kingdom)), Jing Zhou(University of Liverpool), M. Baxter(University of Manchester), Agnès Tort Piella(Liverpool City Council), Neil R. Kitteringham(University of Liverpool), Bernabé Proto Marco(Almirall (Spain))
Cited by 136
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
|Acta Neuropathologica|2012|1k
The tumorigenicity of human embryonic and induced pluripotent stem cells
|Nature reviews. Cancer|2011|886
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
|Nature Cancer|2020|880